Jonathan Chang
Stock Analyst at Leerink Partners
(0.63)
# 3,755
Out of 4,712 analysts
91
Total ratings
29.17%
Success rate
-19.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VINC Vincerx Pharma | Maintains: Outperform | $4 → $2 | $0.33 | +515.38% | 6 | Oct 8, 2024 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $29.03 | +154.91% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $2.99 | +267.89% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $30.08 | +69.55% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $6 → $5 | $0.70 | +614.18% | 12 | Jan 10, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $34 | $12.33 | +175.75% | 9 | Dec 7, 2022 | |
| GMAB Genmab | Maintains: Market Perform | $31 → $33 | $20.77 | +58.88% | 9 | Nov 10, 2022 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $14.13 | +253.86% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $43.17 | -30.51% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $3.23 | +271.52% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $14 | $1.42 | +885.92% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $6.90 | +276.81% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $101 → $95 | $26.47 | +258.90% | 8 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.55 | +441.52% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $8.51 | +229.02% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $23.71 | +123.53% | 7 | Aug 5, 2021 |
Vincerx Pharma
Oct 8, 2024
Maintains: Outperform
Price Target: $4 → $2
Current: $0.33
Upside: +515.38%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $29.03
Upside: +154.91%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $2.99
Upside: +267.89%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $30.08
Upside: +69.55%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $6 → $5
Current: $0.70
Upside: +614.18%
Replimune Group
Dec 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $12.33
Upside: +175.75%
Genmab
Nov 10, 2022
Maintains: Market Perform
Price Target: $31 → $33
Current: $20.77
Upside: +58.88%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $14.13
Upside: +253.86%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $43.17
Upside: -30.51%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $3.23
Upside: +271.52%
Aug 9, 2022
Maintains: Outperform
Price Target: $13 → $14
Current: $1.42
Upside: +885.92%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $6.90
Upside: +276.81%
May 11, 2022
Maintains: Outperform
Price Target: $101 → $95
Current: $26.47
Upside: +258.90%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.55
Upside: +441.52%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $8.51
Upside: +229.02%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $23.71
Upside: +123.53%